|
39 Companies |
|
49 Products |
|
49 Products |
|
46 Mechanisms of Action |
|
0 Trials |
|
259 News |
|
| 123456» |
- | NN1213 / Novo Nordisk
Enrollment change, Trial withdrawal, Metastases: HIPPO-S: HS-PCI in Locally Advanced Adenocarcinoma of the Lung (clinicaltrials.gov) - Apr 17, 2019
P3, N=0, Withdrawn, Sponsor: Universit
N=438 --> 0 | Not yet recruiting --> Withdrawn
- | Avastin (bevacizumab) / Roche, NN1213 / Novo Nordisk
Enrollment change, Trial termination: METAL2: Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases (clinicaltrials.gov) - Feb 1, 2019
P3, N=95, Terminated, Sponsor: Centre Hospitalier Intercommunal Creteil
N=210 --> 95 | Recruiting --> Terminated; Slow inclusions due in part to a change in practices. The first chemotherapy become a standard for patients with NSCL with asymptomatic brain metastases.
- | Enrollment change, Trial withdrawal: Study of Proteins in Tumor Samples From Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jan 24, 2019
P=N/A, N=0, Withdrawn, Sponsor: Alliance for Clinical Trials in Oncology
The first chemotherapy become a standard for patients with NSCL with asymptomatic brain metastases. N=261 --> 0 | Active, not recruiting --> Withdrawn
- | Pozenveo (poziotinib) / Assertio
New P2 trial: NOV120101 Phase 2 Study in NSCLC Patients With Aquired Resistance to 1st Generation EGFR Tyrosine Kinase Inhibitors (clinicaltrials.gov) - Jan 19, 2019
P2, N=40, Active, not recruiting, Sponsor: National OncoVenture
- | carboplatin / Generic mfg., paclitaxel / Generic mfg., sorafenib / Generic mfg.
Enrollment change, Trial withdrawal, Combination therapy: Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jan 10, 2019
P1/2, N=0, Withdrawn, Sponsor: University of Texas Southwestern Medical Center
N=261 --> 0 | Active, not recruiting --> Withdrawn N=84 --> 0 | Terminated --> Withdrawn
- | Avastin (bevacizumab) / Roche
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma. (clinicaltrials.gov) - Dec 20, 2018
P2, N=25, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
N=84 --> 0 | Terminated --> Withdrawn N=60 --> 25 | Trial completion date: Nov 2019 --> Jan 2017 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2015 --> Jan 2017; Low enrollment
- |||| Gilotrif (afatinib) / Boehringer Ingelheim
Trial primary completion date: LUX-Lung 6: BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Dec 14, 2018
P3, N=364, Completed, Sponsor: Boehringer Ingelheim
N=60 --> 25 | Trial completion date: Nov 2019 --> Jan 2017 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2015 --> Jan 2017; Low enrollment Trial primary completion date: Dec 2013 --> Nov 2017
- | sunitinib / Generic mfg.
Trial completion: Sunitinib in Never-Smokers With Lung Adenocarcinoma (clinicaltrials.gov) - Sep 4, 2018
P2, N=13, Completed, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Dec 2013 --> Nov 2017 Active, not recruiting --> Completed
- | Trial completion date, Metastases: Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jul 23, 2018
P3, N=313, Terminated, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Trial completion date: Dec 2016 --> Mar 2018
- | Trial completion, Trial completion date, Surgery: Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed By Surgery (clinicaltrials.gov) - Jun 14, 2018
P2, N=33, Completed, Sponsor: Radiation Therapy Oncology Group
Trial completion date: Dec 2016 --> Mar 2018 Active, not recruiting --> Completed | Trial completion date: May 2020 --> May 2018
- | topotecan / Generic mfg., vinorelbine tartrate / Generic mfg.
Enrollment change, Combination therapy: Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer (clinicaltrials.gov) - Jun 2, 2018
P1, N=18, Completed, Sponsor: Medical University of South Carolina
Active, not recruiting --> Completed | Trial completion date: May 2020 --> May 2018 N=36 --> 18
- ||| Avastin (bevacizumab) / Roche
Trial completion, Trial completion date, Trial primary completion date, Monotherapy, Metastases: A Study Examining Maintenance Bevacizumab (Avastin (clinicaltrials.gov) - Feb 23, 2018
P=N/A, N=201, Completed, Sponsor: Hoffmann-La Roche
N=36 --> 18 Active, not recruiting --> Completed | Trial completion date: Feb 2018 --> Jan 2018 | Trial primary completion date: Feb 2018 --> Jan 2018
- | carboplatin / Generic mfg., erlotinib / Generic mfg.
Trial completion, Surgery: Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Jan 31, 2018
P2, N=78, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed | Trial completion date: Feb 2018 --> Jan 2018 | Trial primary completion date: Feb 2018 --> Jan 2018 Active, not recruiting --> Completed
- erlotinib / Generic mfg., gefitinib / Generic mfg., dasatinib / Generic mfg.
Trial completion, Metastases: Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib (clinicaltrials.gov) - Dec 29, 2017
P2, N=22, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Jakafi (ruxolitinib) / Incyte
Trial completion, Trial primary completion date: Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib (clinicaltrials.gov) - Dec 29, 2017
P1/2, N=22, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jun 2018 --> Oct 2017
- ||||||| Gilotrif (afatinib) / Boehringer Ingelheim
Trial completion: LUX-Lung 6: BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Dec 22, 2017
P3, N=364, Completed, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed | Trial primary completion date: Jun 2018 --> Oct 2017 Active, not recruiting --> Completed
- | carboplatin / Generic mfg., paclitaxel / Generic mfg.
Trial completion: Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer (clinicaltrials.gov) - Dec 21, 2017
P1/2, N=63, Completed, Sponsor: Radiation Therapy Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Avastin (bevacizumab) / Roche
Trial primary completion date, Monotherapy, Metastases: A Study Examining Maintenance Bevacizumab (Avastin (clinicaltrials.gov) - Dec 5, 2017
P=N/A, N=200, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Trial primary completion date: Oct 2017 --> Feb 2018
- || Avastin (bevacizumab) / Roche
Enrollment closed, Monotherapy, Metastases: A Study Examining Maintenance Bevacizumab (Avastin (clinicaltrials.gov) - Oct 3, 2017
P=N/A, N=200, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Oct 2017 --> Feb 2018 Recruiting --> Active, not recruiting
- Trial termination, Trial primary completion date: ONC003: Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-up (clinicaltrials.gov) - Sep 5, 2017
P=N/A, N=227, Terminated, Sponsor: Myriad Genetic Laboratories, Inc.
Recruiting --> Active, not recruiting Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Jun 2017; Company decision to terminate
- Enrollment change, Trial termination, Trial primary completion date: Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006) (clinicaltrials.gov) - Sep 5, 2017
P=N/A, N=44, Terminated, Sponsor: Myriad Genetic Laboratories, Inc.
Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Jun 2017; Company decision to terminate N=250 --> 44 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Jun 2017; company decision to terminate
- | Enrollment change, Trial termination, Trial primary completion date, Metastases: Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Aug 10, 2017
P3, N=313, Terminated, Sponsor: Alliance for Clinical Trials in Oncology
N=250 --> 44 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Jun 2017; company decision to terminate N=792 --> 313 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2019 --> Nov 2013; DSMB recommendation
- | Trial completion, Trial primary completion date: Study of Tumor Samples From Patients With Lung Cancer (clinicaltrials.gov) - Aug 8, 2017
P=N/A, N=280, Completed, Sponsor: Alliance for Clinical Trials in Oncology
N=792 --> 313 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2019 --> Nov 2013; DSMB recommendation Recruiting --> Completed | Trial primary completion date: Jan 2100 --> Feb 2012
- | NN1213 / Novo Nordisk
Enrollment change, Trial initiation date, Trial termination, Metastases: Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer (clinicaltrials.gov) - Jul 28, 2017
P2, N=17, Terminated, Sponsor: Burzynski Research Institute
Recruiting --> Completed | Trial primary completion date: Jan 2100 --> Feb 2012 N=40 --> 17 | Initiation date: Aug 1998 --> Mar 1996 | Active, not recruiting --> Terminated; Slow accrual
- ||| Avastin (bevacizumab) / Roche
Trial completion: AVAdeno Study: An Observational Study of First-Line Avastin (Bevacizumab) in Patients With Adenocarcinoma of the Lung (clinicaltrials.gov) - Jul 28, 2017
P=N/A, N=1107, Completed, Sponsor: Hoffmann-La Roche
N=40 --> 17 | Initiation date: Aug 1998 --> Mar 1996 | Active, not recruiting --> Terminated; Slow accrual Active, not recruiting --> Completed
- | Trial completion, Enrollment change: Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jun 27, 2017
P=N/A, N=248, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Recruiting --> Completed | N=390 --> 248
- | erlotinib / Generic mfg.
Trial completion, Trial primary completion date, Metastases: Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jun 8, 2017
P2, N=116, Completed, Sponsor: Vanderbilt-Ingram Cancer Center
Recruiting --> Completed | N=390 --> 248 Active, not recruiting --> Completed | Trial primary completion date: Dec 2012 --> Sep 2011
- | Avastin (bevacizumab) / Roche
Trial completion, Metastases: Study of Blood and Tissue Samples From Patients With Locally Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Treated With Bevacizumab, Carboplatin, and Paclitaxel (clinicaltrials.gov) - May 19, 2017
P=N/A, N=180, Completed, Sponsor: ECOG-ACRIN Cancer Research Group
Active, not recruiting --> Completed | Trial primary completion date: Dec 2012 --> Sep 2011 Not yet recruiting --> Completed
- | Avastin (bevacizumab) / Roche
Biomarker, Trial completion, Trial primary completion date, Combination therapy: Biomarker Study of Blood Samples From Patients With Non-Small Cell Lung Cancer Treated With Carboplatin and Paclitaxel With or Without Bevacizumab (clinicaltrials.gov) - May 19, 2017
P=N/A, N=90, Completed, Sponsor: ECOG-ACRIN Cancer Research Group
Not yet recruiting --> Completed Not yet recruiting --> Completed | Trial primary completion date: Apr 2009 --> Apr 2008
- | erlotinib / Generic mfg.
Trial completion: Development of a Model to Predict Progression-Free Survival After Erlotinib in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - May 19, 2017
P=N/A, N=137, Completed, Sponsor: ECOG-ACRIN Cancer Research Group
Not yet recruiting --> Completed | Trial primary completion date: Apr 2009 --> Apr 2008 Active, not recruiting --> Completed
- ||| Biomarker, Trial completion: Biomarkers for Diagnosis of Lung Cancer (clinicaltrials.gov) - May 12, 2017
P=N/A, N=300, Completed, Sponsor: SK Medical (Beijing) Co., Ltd.
Active, not recruiting --> Completed Recruiting --> Completed
- Jakafi (ruxolitinib) / Incyte
Trial primary completion date: Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib (clinicaltrials.gov) - Apr 18, 2017
P1/2, N=22, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Completed Trial primary completion date: Jun 2017 --> Jun 2018
- | Avastin (bevacizumab) / Roche
Trial completion, Trial primary completion date: Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers (clinicaltrials.gov) - Apr 18, 2017
P2, N=39, Completed, Sponsor: UNC Lineberger Comprehensive Cancer Center
Trial primary completion date: Jun 2017 --> Jun 2018 Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> May 2016
- | Trial completion, HEOR, Adherence: Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care (clinicaltrials.gov) - Apr 7, 2017
P=N/A, N=1440, Completed, Sponsor: Fox Chase Cancer Center
Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> May 2016 Recruiting --> Completed
- ||||||| Gilotrif (afatinib) / Boehringer Ingelheim
Trial completion: LUX-Lung 3: BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation (clinicaltrials.gov) - Apr 4, 2017
P3, N=345, Completed, Sponsor: Boehringer Ingelheim
Recruiting --> Completed Active, not recruiting --> Completed
- sunitinib / Generic mfg.
Enrollment closed, Enrollment change: Sunitinib in Never-Smokers With Lung Adenocarcinoma (clinicaltrials.gov) - Jan 23, 2017
P2, N=13, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=35 --> 13
- | cisplatin / Generic mfg., gemcitabine / Generic mfg.
Trial completion: Gemcitabine Plus Radiation Therapy or Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer (clinicaltrials.gov) - Jan 18, 2017
P1/2, N=40, Completed, Sponsor: Wake Forest University Health Sciences
Recruiting --> Active, not recruiting | N=35 --> 13 No longer recruiting --> Completed
- Avastin (bevacizumab) / Roche
Enrollment closed, Trial primary completion date, Metastases: Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma. (clinicaltrials.gov) - Oct 13, 2016
P2, N=60, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
No longer recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Nov 2015
- metformin / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date, Metastases: Metformin in Stage IV Lung Adenocarcinoma (clinicaltrials.gov) - Sep 30, 2016
P2, N=13, Terminated, Sponsor: National Cheng-Kung University Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Nov 2015 N=48 --> 13 | Recruiting --> Terminated | Trial primary completion date: Nov 2015 --> Jun 2016; Difficult enrollment
- buparlisib (AN2025) / Novartis, Adlai Nortye
Trial completion, Enrollment change, Combination therapy, Metastases: PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Sep 20, 2016
P1, N=9, Completed, Sponsor: City of Hope Medical Center
N=48 --> 13 | Recruiting --> Terminated | Trial primary completion date: Nov 2015 --> Jun 2016; Difficult enrollment Active, not recruiting --> Completed | N=39 --> 9
- | SNX-5422 / Esanex
Trial completion: Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma (clinicaltrials.gov) - Aug 16, 2016
P1, N=17, Completed, Sponsor: Esanex Inc.
Active, not recruiting --> Completed | N=39 --> 9 Active, not recruiting --> Completed
- sunitinib / Generic mfg.
Trial primary completion date: Sunitinib in Never-Smokers With Lung Adenocarcinoma (clinicaltrials.gov) - Aug 11, 2016
P2, N=35, Recruiting, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed Trial primary completion date: Jun 2016 --> Aug 2017
- | irinotecan / Generic mfg., docetaxel / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Metastases: Gemcitabine Plus Docetaxel or Irinotecan in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer (clinicaltrials.gov) - Jul 18, 2016
P2, N=80, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Jun 2016 --> Aug 2017 Active, not recruiting --> Completed
- | irofulven-1 (LP-100) / Lantern Pharma, Eisai
Trial completion: Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer (clinicaltrials.gov) - Jul 18, 2016
P2, N=36, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | carboplatin / Generic mfg., paclitaxel / Generic mfg.
Trial completion, Surgery: Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery (clinicaltrials.gov) - Jul 18, 2016
P3, N=366, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Combination Chemotherapy and Computer-Planned Radiation Therapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jul 17, 2016
P2, N=69, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Karenitecin (cositecan) / BioNumerik
Trial completion: Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jul 17, 2016
P2, N=55, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer And Lung Dysfunction (clinicaltrials.gov) - Jul 12, 2016
P1, N=39, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Positron Emission Tomography for Detecting Non-small Cell Lung Cancer (clinicaltrials.gov) - Jul 11, 2016
P=N/A, N=303, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed No longer recruiting --> Completed
- fluoxetine / Generic mfg.
Trial completion, HEOR, Metastases: Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jul 6, 2016
P2, N=21, Completed, Sponsor: Alliance for Clinical Trials in Oncology
No longer recruiting --> Completed Terminated --> Completed